However, KDM6A appears to function as a tumor suppressor (113), and recent results implicate KDM6A loss in bladder cancer progression (114) and resistance to the CD38 blocker daratumumab in multiple myeloma (115), potentially contraindicating the general use of KDM6A/B inhibitors. This evidence concerns the gene KDM6A and urinary bladder carcinoma.